Combined anti-tumor effects of IFN-α and sorafenib on hepatocellular carcinoma in vitro and in vivo

Biochemical and Biophysical Research Communications

Volumn 422, Issue 4, 2012, Pages 687-692

  Wang, Lijing ^a   Jia, Dongwei ^a   Duan, Fangfang ^a   Sun, Zhichao ^a   Liu, Xiaojuan ^a   Zhou, Lei ^a   Sun, Linlin ^a   Ren, Shifang ^a   Ruan, Yuanyuan ^a   Gu, Jianxin ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Combination therapy; Hepatocellular carcinoma; Interferon ; Sorafenib

Indexed keywords

CYCLIN A; CYCLIN B; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MCL 1; RECOMBINANT ALPHA INTERFERON; SORAFENIB; STAT1 PROTEIN; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC PROTOCOLS; BCL-X PROTEIN; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; CYCLIN A; CYCLIN B; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDINES; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR;

EID: 84862277821     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.05.056     Document Type: Article

References (36)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
3. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917.
4. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 2005, 5:375-386.
5. Gutterman J.U. Cytokine therapeutics: lessons from interferon alpha. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:1198-1205.
6. Bracarda S., Eggermont A.M., Samuelsson J. Redefining the role of interferon in the treatment of malignant diseases. Eur. J. Cancer 2010, 46:284-297.
7. Feldman D.R., Kondagunta G.V., Schwartz L., Patil S., Ishill N., DeLuca J., Russo P., Motzer R.J. Phase II trial of pegylated interferon-alpha 2b in patients with advanced renal cell carcinoma. Clin. Genitourin Cancer 2008, 6:25-30.
8. Hansson J., Aamdal S., Bastholt L., Brandberg Y., Hernberg M., Nilsson B., Stierner U., von der Maase H. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol. 2011, 12:144-152.
9. Simonsson B., Hjorth-Hansen H., Bjerrum O.W., Porkka K. Interferon alpha for treatment of chronic myeloid leukemia. Curr. Drug Targets 2011, 12:420-428.
10. Yano H., Iemura A., Haramaki M., Ogasawara S., Takayama A., Akiba J., Kojiro M. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology 1999, 29:1708-1717.
11. Zhang T., Sun H.C., Zhou H.Y., Luo J.T., Zhang B.L., Wang P., Wang L., Qin L.X., Ren N., Ye S.L., Li Q., Tang Z.Y. Interferon alpha inhibits hepatocellular carcinoma growth through inducing apoptosis and interfering with adhesion of tumor endothelial cells. Cancer Lett. 2010, 290:204-210.
12. Llovet J.M., Sala M., Castells L., Suarez Y., Vilana R., Bianchi L., Ayuso C., Vargas V., Rodes J., Bruix J. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000, 31:54-58.
13. Kudo M. Adjuvant therapy after curative treatment for hepatocellular carcinoma. Oncology 2011, 81(Suppl. 1):50-55.
14. Patt Y.Z., Hassan M.M., Lozano R.D., Brown T.D., Vauthey J.N., Curley S.A., Ellis L.M. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J. Clin. Oncol. 2003, 21:421-427.
15. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L., Lynch M., Auclair D., Taylor I., Gedrich R., Voznesensky A., Riedl B., Post L.E., Bollag G., Trail P.A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64:7099-7109.
16. Wilhelm S., Carter C., Lynch M., Lowinger T., Dumas J., Smith R.A., Schwartz B., Simantov R., Kelley S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discovery 2006, 5:835-844.
17. Liu L., Cao Y., Chen C., Zhang X., McNabola A., Wilkie D., Wilhelm S., Lynch M., Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006, 66:11851-11858.
18. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., de Oliveira A.C., Santoro A., Raoul J.L., Forner A., Schwartz M., Porta C., Zeuzem S., Bolondi L., Greten T.F., Galle P.R., Seitz J.F., Borbath I., Haussinger D., Giannaris T., Shan M., Moscovici M., Voliotis D., Bruix J. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359:378-390.
19. Dal Lago L., D'Hondt V., Awada A. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist 2008, 13:845-858.
20. Escudier B., Szczylik C., Hutson T.E., Demkow T., Staehler M., Rolland F., Negrier S., Laferriere N., Scheuring U.J., Cella D., Shah S., Bukowski R.M. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009, 27:1280-1289.
21. Ruan Y., Guo L., Qiao Y., Hong Y., Zhou L., Sun L., Wang L., Zhu H., Yun X., Xie J., Gu J. RACK1 associates with CLEC-2 and promotes its ubiquitin-proteasome degradation. Biochem. Biophys. Res. Commun. 2009, 390:217-222.
22. Liu H., Xu J., Zhou L., Yun X., Chen L., Wang S., Sun L., Wen Y., Gu J. Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway. Cancer Res. 2011, 71:7547-7557.
23. Wang L., Tang Z.Y., Qin L.X., Wu X.F., Sun H.C., Xue Q., Ye S.L. High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology 2000, 32:43-48.
24. Murphy D., Detjen K.M., Welzel M., Wiedenmann B., Rosewicz S. Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology 2001, 33:346-356.
25. Herzer K., Hofmann T.G., Teufel A., Schimanski C.C., Moehler M., Kanzler S., Schulze-Bergkamen H., Galle P.R. IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53. Cancer Res. 2009, 69:855-862.
26. Dimberg A., Karlberg I., Nilsson K., Oberg F. Ser727/Tyr701-phosphorylated Stat1 is required for the regulation of c-Myc, cyclins, and p27Kip1 associated with ATRA-induced G0/G1 arrest of U-937 cells. Blood 2003, 102:254-261.
27. Wei H., Xu L., Yu M., Zhang L., Wang H., Wei X., Ruan Y. Monocillin II inhibits human breast cancer growth partially by inhibiting MAPK pathways and CDK2 Thr160 phosphorylation. ChemBioChem 2012, 13:465-475.
28. Meng X.W., Lee S.H., Dai H., Loegering D., Yu C., Flatten K., Schneider P., Dai N.T., Kumar S.K., Smith B.D., Karp J.E., Adjei A.A., Kaufmann S.H. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J. Biol. Chem. 2007, 282:29831-29846.
29. Ricci M.S., Kim S.H., Ogi K., Plastaras J.P., Ling J., Wang W., Jin Z., Liu Y.Y., Dicker D.T., Chiao P.J., Flaherty K.T., Smith C.D., El-Deiry W.S. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 2007, 12:66-80.
30. Fernando J., Sancho P., Fernandez-Rodriguez C.M., Lledo J.L., Caja L., Campbell J.S., Fausto N., Fabregat I. Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli. J. Cell Physiol. 2012, 227:1319-1325.
31. Legrand A., Vadrot N., Lardeux B., Bringuier A.F., Guillot R., Feldmann G. Study of the effects of interferon a on several human hepatoma cell lines: analysis of the signalling pathway of the cytokine and of its effects on apoptosis and cell proliferation. Liver Int. 2004, 24:149-160.
32. Whittaker S., Marais R., Zhu A.X. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010, 29:4989-5005.
33. Calvisi D.F., Ladu S., Gorden A., Farina M., Conner E.A., Lee J.S., Factor V.M., Thorgeirsson S.S. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006, 130:1117-1128.
34. He G., Karin M. NF-kappaB and STAT3 - key players in liver inflammation and cancer. Cell Res. 2011, 21:159-168.
35. Chai H., Luo A.Z., Weerasinghe P., Brown R.E. Sorafenib downregulates ERK/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line. Int. J. Clin. Exp. Pathol. 2010, 3:408-415.
36. Tai W.T., Cheng A.L., Shiau C.W., Huang H.P., Huang J.W., Chen P.J., Chen K.F. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J. Hepatol. 2011, 55:1041-1048.